Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
The purpose of the protocol is to assess the efficacy and safety of BIM 23A760 on patient's overall satisfaction in terms of symptom relief (diarrhoea and/or flushes) in patients with carcinoid syndrome after 24 weeks of treatment.
Carcinoid Syndrome
DRUG: BIM 23A760
Percentage of Patients With a Positive Overall Satisfactory Relief of Symptoms (Diarrhoea and/or Flushes) on the Likert Scale, Patient satisfaction based on a Likert scale from 0-5 (0 being not satisfied and 5 being completely satisfied), Week 24
Percentage of Patients With Improvement in Symptoms (Diarrhoea and/or Flushes), Up to week 24|Change in the Quality of Life (QoL) Assessment, Week 24|Change in 5 Hydroxyindoleacetic Acid (5 HIAA) and Chromogranin A, Week 24|Number of Subjects Reported Adverse Events, Including Any Findings From an Examination of the Injection Site(s), Up to week 26|Minimum Concentration (Cmin) BIM 23A760 Plasma Levels, At 9 timepoints up to 1 week after 24th administration in week 24|Concentration at 2 Hours Postdose (C2 Hours) BIM 23A760 Plasma Levels, At 8 timepoints up to week 24
The purpose of the protocol is to assess the efficacy and safety of BIM 23A760 on patient's overall satisfaction in terms of symptom relief (diarrhoea and/or flushes) in patients with carcinoid syndrome after 24 weeks of treatment.